What is he best known for?
The fields of study he is best known for:
- Internal medicine
- Myocardial infarction
- Heart failure
His scientific interests lie mostly in Internal medicine, Cardiology, Myocardial infarction, Heart failure and Surgery.
Hazard ratio, Ejection fraction, Heart disease, Atrial fibrillation and Confidence interval are the primary areas of interest in his Internal medicine study.
His Cardiology research incorporates elements of Clinical endpoint and Randomized controlled trial.
His Myocardial infarction research is multidisciplinary, incorporating perspectives in Stroke, ACE inhibitor and Risk factor.
In his work, Captopril is strongly intertwined with Valsartan, which is a subfield of Heart failure.
His Surgery study incorporates themes from Clinical trial, Risk of mortality, Epidemiology, Cohort study and Comorbidity.
His most cited work include:
- ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. (5331 citations)
- Valsartan, Captopril, or Both in Myocardial Infarction Complicated by Heart Failure, Left Ventricular Dysfunction, or Both (2012 citations)
- ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012 (1893 citations)
What are the main themes of his work throughout his whole career to date?
The scientist’s investigation covers issues in Internal medicine, Cardiology, Heart failure, Myocardial infarction and Hazard ratio.
He merges Internal medicine with In patient in his research.
Lars Køber studied Cardiology and Surgery that intersect with Epidemiology.
The Heart failure study combines topics in areas such as Incidence, Clinical endpoint, Randomized controlled trial, Dapagliflozin and Valsartan.
His work carried out in the field of Myocardial infarction brings together such families of science as Heart disease and Risk factor.
His study in Hazard ratio is interdisciplinary in nature, drawing from both Interquartile range, Cohort study, Cohort and Comorbidity.
He most often published in these fields:
- Internal medicine (84.47%)
- Cardiology (60.93%)
- Heart failure (38.04%)
What were the highlights of his more recent work (between 2019-2021)?
- Internal medicine (84.47%)
- Cardiology (60.93%)
- Heart failure (38.04%)
In recent papers he was focusing on the following fields of study:
Lars Køber mainly investigates Internal medicine, Cardiology, Heart failure, Hazard ratio and Ejection fraction.
As part of his studies on Internal medicine, he often connects relevant areas like Dapagliflozin.
His Cardiology study integrates concerns from other disciplines, such as Clinical endpoint and Interquartile range.
His work in Heart failure tackles topics such as Diabetes mellitus which are related to areas like Mace and Kidney disease.
His research in Hazard ratio intersects with topics in Blood pressure and Cohort study.
Lars Køber works mostly in the field of Ejection fraction, limiting it down to topics relating to Placebo and, in certain cases, Empagliflozin.
Between 2019 and 2021, his most popular works were:
- Association of Angiotensin-Converting Enzyme Inhibitor or Angiotensin Receptor Blocker Use With COVID-19 Diagnosis and Mortality. (195 citations)
- Effect of dapagliflozin on worsening heart failure and cardiovascular death in patients with heart failure with and without diabetes (76 citations)
- Sacubitril/Valsartan Across the Spectrum of Ejection Fraction in Heart Failure (71 citations)
In his most recent research, the most cited papers focused on:
- Internal medicine
- Heart failure
- Myocardial infarction
His primary areas of investigation include Internal medicine, Heart failure, Cardiology, Ejection fraction and Hazard ratio.
His Atrial fibrillation, Confidence interval and Myocardial infarction study in the realm of Internal medicine interacts with subjects such as In patient.
His Heart failure research is multidisciplinary, relying on both Genome-wide association study, Cohort study, Diabetes mellitus, Electrocardiography and Mendelian inheritance.
His research integrates issues of Magnetic resonance imaging, Cardiac magnetic resonance imaging, Clinical endpoint, Fibrosis and Hyperkalemia in his study of Cardiology.
His Ejection fraction study combines topics from a wide range of disciplines, such as Valsartan, Placebo, Randomized controlled trial and MEDLINE.
His Hazard ratio research includes themes of Absolute risk reduction, Interquartile range, Proportional hazards model and Cohort.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
